Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Spectris shares pop as KKR responds to Advent bid

(Sharecast News) - Shares in instrumentation business Spectris were up more than 15% in early trading after a bidding war between Advent and KKR started to heat up. Private equity investor Advent said on Monday that it had reached an agreement on the terms of a recommended cash acquisition.

Advent will pay £37.63 for every Spectris share, including £37.35 in cash from Bidco and an interim dividend of 28.0p, representing an "attractive premium" of approximately 84.6p to its closing price on 6 June and valuing the business at approximately £3.8bn.

However, Kohlberg Kravis Roberts & Co, which has been engaging constructively with Spectris since submitting its first proposal on 2 June, later confirmed that while no revised proposal has yet been made, it was "actively engaged" in the advanced stages of due diligence and arranging financing commitments.

KKR also strongly encouraged Spectris shareholders to take no action with regard to the Advent offer.

AJ Bell's Russ Mould said: "Advent has struck a deal to buy Spectris at a chunky premium to the market value before bid interest was revealed earlier this month. Spectris' board has recommended the all-cash offer and it's now up to shareholders to vote on it. KKR has already expressed interest in Spectris and will need to make a formal offer fast if it stands a chance of derailing the Advent bid.

"The fact we've got two bid battles in Spectris and Assura just goes to show how the UK stock market continues to be on sale. If investors don't recognise the good value opportunities on offer, trade buyers or private equity firms will keep swooping on targets and pick them off one by one."

As of 1310 BST, Spectris shares had rallied 15.48% to 3,790.20p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.